AVITA Medical, Inc.
CHIA:AVH Stok Raporu
AVITA Medical Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6 AVITA Medical şirketinin kazançları yıllık ortalama -5.8% oranında azalırken, Biotechs sektörünün kazançları yıllık 12.6% oranında artan oldu. Gelirler yıllık ortalama 30.1% oranında artan oldu.
Anahtar bilgiler Biotechs Sektör Büyümesi 9.6% Gelir büyüme oranı 30.1% Özkaynak getirisi -468.8% Net Marj -95.5% Son Kazanç Güncellemesi 30 Sep 2024
Yakın geçmiş performans güncellemeleri
AVITA Medical, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 11
AVITA Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 12 AVITA Medical, Inc. to Report Q3, 2024 Results on May 13, 2024
AVITA Medical, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 02
AVITA Medical, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 20
Second quarter 2023 earnings released: US$0.082 loss per share (vs US$0.05 loss in 2Q 2022) Aug 11
Tüm güncellemeleri göster
AVITA Medical, Inc. Provides Financial Guidance for Fourth Quarter and Full Year of 2024 Nov 09
AVITA Medical, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 11
AVITA Medical, Inc. Provides Financial Guidance for Third Quarter 2024 and Updates Financial Guidance for Full Year 2024 Aug 09
AVITA Medical, Inc. Names Robin Vandenburgh as SVP of U.S. Commercial Sales Aug 02
AVITA Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 12
AVITA Medical, Inc. Announces Executive Changes Jul 02
AVITA Medical, Inc. Announces FDA Approval of RECELL GO May 31
AVITA Medical, Inc. Provides Earnings Guidance for the Second of 2024 May 15
AVITA Medical, Inc., Annual General Meeting, Jun 05, 2024 Apr 24 AVITA Medical, Inc. to Report Q3, 2024 Results on May 13, 2024
AVITA Medical, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 Feb 24
AVITA Medical, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 02
Avita Medical, Inc. Provides Preliminary Revenue Guidance for Fourth Quarter and Full-Year 2023 and First Quarter and Year 2024 Jan 10
AVITA Medical, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 20 AVITA Medical, Inc. announced that it expects to receive $90 million in funding from OrbiMed Advisors LLC
New minor risk - Shareholder dilution Aug 29
New minor risk - Profitability Aug 13
AVITA Medical, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023 Aug 11
Second quarter 2023 earnings released: US$0.082 loss per share (vs US$0.05 loss in 2Q 2022) Aug 11
AVITA Medical, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 23 AVITA Medical, Inc. Submits FDA PMA Supplement for Recell Go Jun 30
AVITA Medical, Inc. Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients Jun 17
AVITA Medical, Inc. Announces Appointment of David O’Toole as Chief Financial Officer Jun 16
AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects Jun 08
First quarter 2023 earnings released: US$0.073 loss per share (vs US$0.076 loss in 1Q 2022) May 13
AVITA Medical, Inc. Expects FDA Submission of Recell Go by June 30, 2023 May 13
AVITA Medical, Inc. Announces Executive Changes May 12
Full year 2022 earnings released: US$0.21 loss per share (vs US$0.23 loss in FY 2021) Feb 25 AVITA Medical, Inc. to Report Q4, 2022 Results on Feb 23, 2023
AVITA Medical, Inc. Submits FDA PMA Application for Vitiligo Dec 20
AVITA Medical, Inc. Submits PMA Supplement for Soft Tissue Repair Dec 13
Third quarter 2022 earnings released: US$0.045 loss per share (vs US$0.048 loss in 3Q 2021) Nov 16
Third quarter 2022 earnings released: US$0.045 loss per share (vs US$0.048 loss in 3Q 2021) Nov 13
AVITA Medical, Inc. Revises Financial Guidance for the Year 2022 Nov 11
AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL System for Soft Tissue Repair Nov 10
AVITA Medical, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 21
AVITA Medical, Inc., Annual General Meeting, Dec 12, 2022 Oct 20
AVITA Medical, Inc. Announces Executive Changes Sep 30
AVITA Medical, Inc. Announces Chief Executive Officer Changes Sep 29
AVITA Medical, Inc. Announces Positive Topline Results from A Pivotal Randomized, Controlled Trial Evaluating the Safety and Effectiveness of the RECELL® System for Repigmentation of Stable Vitiligo Lesions Sep 13
RECELL Insurance Coverage Begins in Japan for Acute Burns Sep 02
Second quarter 2022 earnings released: US$0.05 loss per share (vs US$0.038 loss in 2Q 2021) Aug 13 AVITA Medical, Inc. Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries Using the Recell System
AVITA Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Jul 26 AVITA Medical, Inc.(NasdaqCM:RCEL) dropped from Russell 2000 Growth Index
Avita Medical, Inc. Provides Guidance for Year 2022 May 13
Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors Apr 22
Forecast to breakeven in 2024 Mar 04
Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations Mar 03
AVITA Medical, Inc. Provides Revenue Guidance for the Calendar Year 2022 Mar 01
AVITA (AVH) Announces RECELL Receives Japan PMDA Approval Feb 24
AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use Feb 18
AVITA Medical, Inc. to Report First Half, 2022 Results on Feb 28, 2022 Feb 16
Forecast to breakeven in 2024 Jan 21 AVITA Medical, Inc. Establishes Proof of Concept for Gene Therapy
Forecast to breakeven in 2024 Dec 28
AVITA Medical, Inc. Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable Vitiligo Dec 16
First quarter 2022 earnings released: US$0.048 loss per share (vs US$0.095 loss in 1Q 2021) Nov 10
Full year 2021 earnings released: US$0.23 loss per share (vs US$0.41 loss in FY 2020) Aug 28
AVITA Medical, Inc. Provides Revenue Guidance for the First Quarter of Fiscal Year 2022 Aug 27
FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical, Inc.'s Pivotal Study of the RECELL® System for Vitiligo Treatment Aug 17
AVITA Medical, Inc. Provides Revenue Guidance for the Fourth Quarter Ending June 30, 2021 Jun 18
Avita Medical, Inc. Announces Preliminary Unaudited Financial Results for the Fiscal Fourth Quarter Ending June 30, 2021 Jun 16
U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients Jun 11
Forecast to breakeven in 2024 May 19
Third quarter 2021 earnings released: US$0.053 loss per share (vs US$0.14 loss in 3Q 2020) May 15
AVITA Medical, Inc. Provides Earnings Guidance for 2021 May 14
AVITA Medical, Inc. Will Not Provide Financial Guidance At This Time Feb 12 AVITA Medical, Inc. to Report Q2, 2021 Results on Feb 11, 2021
New 90-day high: AU$6.80 Jan 20
New 90-day low: AU$5.61 Dec 08
AVITA Therapeutics, Inc. Appoints Kathy McGee as Chief Operating Officer, Effective December 1, 2020 Dec 01
Revenue beats expectations Nov 11
First quarter 2021 earnings released: US$0.095 loss per share Nov 11
AVITA Therapeutics and the Houston Methodist Research Institute Enter into Collaboration to Explore Novel Approaches for Skin Rejuvenation Nov 09 AVITA Therapeutics, Inc. Announces Executive Changes
New 90-day low: AU$5.96 Oct 31
AVITA Therapeutics, Inc. to Report Q1, 2021 Results on Nov 11, 2020 Oct 28
Full year earnings released - AU$0.41 loss per share Aug 29
New 90-day low - AU$6.03 Aug 25
AVITA Therapeutics, Inc. to Report Q4, 2020 Results on Aug 27, 2020 Aug 14
New 90-day low - AU$6.15 Jul 30
AVITA Therapeutics Files Form 15 Jul 22
AVITA Medical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi CHIA:AVH Gelir, gider ve kazançlar (USD Millions ) Tarih Gelir Kazançlar G+A Giderleri Ar-Ge Giderleri 30 Sep 24 60 -57 88 22 30 Jun 24 54 -50 80 21 31 Mar 24 51 -45 72 21 31 Dec 23 50 -35 66 21 30 Sep 23 45 -34 59 17 30 Jun 23 41 -31 53 17 31 Mar 23 37 -26 48 15 31 Dec 22 34 -27 45 14 30 Sep 22 32 -30 44 15 30 Jun 22 30 -30 43 14 31 Mar 22 32 -29 41 15 31 Dec 21 33 -25 38 16 30 Sep 21 31 -22 34 15 30 Jun 21 29 -27 37 15 31 Mar 21 23 -35 42 13 31 Dec 20 18 -44 50 11 30 Sep 20 16 -49 54 11 30 Jun 20 14 -42 49 9 31 Mar 20 12 -36 43 8 31 Dec 19 11 -28 35 7 30 Sep 19 8 -23 29 7 30 Jun 19 5 -25 28 8 31 Mar 19 4 -22 27 6 31 Dec 18 2 -18 17 10 30 Sep 18 1 -15 15 10 30 Jun 18 1 -13 16 6 31 Mar 18 1 -12 12 8 31 Dec 17 1 -11 12 7 30 Sep 17 1 -10 11 6 30 Jun 17 1 -9 11 5 31 Mar 17 1 -8 10 4 31 Dec 16 1 -7 8 3 30 Sep 16 1 -8 9 3 30 Jun 16 1 -8 8 3 31 Mar 16 1 -8 7 3 31 Dec 15 1 -7 5 3 30 Sep 15 1 -6 5 3 30 Jun 15 1 -6 4 3 31 Mar 15 1 -5 4 2 31 Dec 14 1 -5 5 2 30 Sep 14 2 -5 6 2 30 Jun 14 3 -5 7 2 31 Mar 14 3 -6 7 2 31 Dec 13 3 -7 8 2
Kaliteli Kazançlar: AVH şu anda kârlı değil.
Büyüyen Kar Marjı: AVH şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: AVH kârlı değildir ve zararlar son 5 yılda yılda 5.8% oranında artmıştır.
Büyüme Hızlandırma: AVH 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: AVH kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 3.4% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: AVH hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi 'ne ( -468.81% ) sahiptir.
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}